Anakinra for the treatment of rheumatoid arthritis;Anakinra til behandling af reumatoid artrit

Ugeskrift for Laeger

Volumn 165, Issue 39, 2003, Pages 3720-3724

  Loft, Anne Gitte Rasmussen ^a   Tarp, Ulrik ^b   Thomsen, Bjarne Svalgaard ^b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIALOGLYCOPROTEIN;

ABDOMINAL PAIN; ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG SAFETY; ERYTHEMA; HUMAN; INFECTION; INJECTION SITE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; ARTICLE; DRUG COMBINATION; EVIDENCE BASED MEDICINE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RANDOMIZED CONTROLLED TRIALS; SIALOGLYCOPROTEINS;

EID: 0142091807     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (19)

1. Dayer JM, Feige U, Edwards CK et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001;13:170-6.
2. Graudal NA, Svenson M, Tarp U et al. Autoantibodies against interleukin 1a in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis 2002;61:598-602.
3. Deleuran BW, Chu CQ, Field M et al. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992;31:801-9.
4. Bresnihan B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Bio Drugs 2001;15:87-97:
5. Cunnane G, Madigan A, Murphy E et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatol 2001;40:62-9.
6. The European Agency for the Evaluation of Medicinal Products. http//:www.eudra.org/humandocs/Humans/EPAR/kineret/kineret.htm/marts, 2003.
7. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
8. Shekelle PG, Woolf SH, Eccles M et al. Clinical guidelines. Developing guidelines. BMJ 1999;318:593-6.
9. Bresnihan B, Alvaro-Garcia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
10. Fleischman R, Tesser J, Schechtman J et al. A safety trial of anakinra: recombinant interleukin-1 receptor antagonist (IL-1ra), in a large placebo controlled heterogenoeous population of patients with rheumatoid arthritis. Arthritis Rheum 2001;44(suppl 9):S84.
11. Schiff MH, Bulpitt K, Weaver AA et al. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Arthritis Rheum 2001;44(suppl 9):S79.
12. Calabrese LH. Anakinra treatment of patients with rheumatoid arthritis. Ann Pharmacother 2002;36:1204-9.
13. Institut for Rationel Farmakoterapi. TNF-α hæmmende behandling. http://www.irf.dk/dk/publikationer/tnf-alfa_haemmende_behandling_02.htm/ marts 2003.
14. Nuki G, Bresnihan B, Bear MB et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2838-46.
15. Jiang Y, Genant HK, Watt I et al. A multicenter double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1001-9.
16. Furst DE, Breedveld FC, Kalden JR et al. Consensus statement. Updated consensus statement on biological agents for the treatmet of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002;61 (suppl II):ii2-ii7.
17. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the medication of rheumatoid arthritis. Ann Rheum Dis 2000;59(suppl 1):i103-8.
18. Dayer JM, Bresnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:574-8.
19. Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002;61:960-7.